Evaluation of Crohn's disease activity: Initial validation of a magnetic resonance enterography global score (MEGS) against faecal calprotectin

European Radiology

Volumn 24, Issue 2, 2014, Pages 277-287

  Makanyanga, Jesica C ^a   Pendsé, Doug ^b   Dikaios, Nikolaos ^a   Bloom, Stuart ^b   McCartney, Sara ^b   Helbren, Emma ^a,b   Atkins, Elaine ^b   Cuthbertson, Terry ^b   Punwani, Shonit ^a,b   Forbes, Alastair ^b   Halligan, Steve ^a,b   Taylor, Stuart A ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

C reactive protein; Calprotectin; Crohn's disease; Inflammatory bowel diseases; Magnetic resonance imaging

Indexed keywords

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; COLON; CROHN DISEASE; FECES; FEMALE; FOLLOW-UP STUDIES; HUMANS; ILEUM; LEUKOCYTE L1 ANTIGEN COMPLEX; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; ROC CURVE; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84895076929     PISSN: 09387994     EISSN: 14321084     Source Type: Journal    
DOI: 10.1007/s00330-013-3010-z     Document Type: Article

References (38)

1. Dignass A, Van Assche G, Lindsay JO et al (2010) The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: current management. J Crohn's Colitis 4:28-62
2. Lichtenstein GR, Hanauer SB, Sandborn WJ (2009) Management of Crohn's disease in adults. Am J Gastroenterol 104:465-483
3. Jones J, Loftus EV, Panaccione R et al (2008) Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol 6:1218-1224
4. Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ (2008) Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol 103:162-169
5. Røseth AG, Schmidt PN, Fagerhol MK (1999) Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol 34:50-54
6. Schoepfer AM, Beglinger C, Straumann A et al (2009) Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol 105:162-169
7. Sipponen T, Kärkkäinen P, Savilahti E et al (2008) Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Aliment Pharmacol Ther 28:1221-1229
8. Sipponen T, Savilahti E, Kolho K-L, Nuutinen H, Turunen U, Färkkilä M (2008) Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis 14:40-46
9. Steward MJ, Punwani S, Proctor I et al (2012) Non-perforating small bowel Crohn's disease assessed by MRI enterography: derivation and histopathological validation of an MR-based activity index. Eur J Radiol 81:2080-2088
10. Zappa M, Stefanescu C, Cazals-Hatem D et al (2011) Which magnetic resonance imaging findings accurately evaluate inflammation in small bowel Crohn's disease? A retrospective comparison with surgical pathologic analysis. Inflamm Bowel Dis 17:984-993
11. Rimola J, Rodriguez S, García-Bosch O et al (2009) Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohn's disease. Gut 58:1113-1120
12. Lasocki A, Pitman A, Williams R, Lui B, Kalade AV, Farish S (2011) Relative efficacy of different MRI signs in diagnosing active Crohn's disease, compared against a histological gold standard. J Magn Reson Imaging 55:11-19
13. Jaffe TA, Gaca AM, Delaney S et al (2007) Radiation doses from small-bowel follow-through and abdominopelvic MDCT in Crohn's disease. AJR Am J Roentgenol 189:1015-1022
14. Peloquin J, Pardi D, Sandborn W et al (2008) Diagnostic ionizing radiation exposure in a population-based cohort of patients with inflammatory bowel disease. Am J Gastroenterol 103:2015-2022
15. Rimola J, Ordás I, Rodriguez S et al (2011) Magnetic resonance imaging for evaluation of Crohn's disease: validation of parameters of severity and quantitative index of activity. Inflamm Bowel Dis 17:1759-1768
16. Taylor SA, Punwani S, Rodriguez-Justo M et al (2009) Mural Crohn disease: correlation of dynamic contrast-enhanced MR imaging findings with angiogenesis and inflammation at histologic examination - Pilot study1. Radiology 251:369-379
17. Ziech MLW, Bipat S, Roelofs J et al (2010) Retrospective comparison of magnetic resonance imaging features and histopathology in Crohn's disease patients. Eur J Radiol 80:e299-e305
18. Harvey R, Bradshaw J (1980) A simple index of Crohn's disease activity. Lancet 1:514
19. Silverberg MS, Satsangi J, Ahmad T et al (2005) Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 19(Suppl A):5-36
20. Lauenstein T, Schneemann H (2003) Optimization of oral contrast agents for MR imaging of the small bowel. Radiology 228:279-283
21. Ajaj WM, Lauenstein TC, Pelster G et al (2005) Magnetic resonance colonography for the detection of inflammatory diseases of the large bowel: quantifying the inflammatory activity. Gut 54:257-263
22. Taylor SA, Halligan S, Goh V et al (2003) Optimizing colonic distention for multi-detector row CT colonography: effect of hyoscine butylbromide and rectal balloon catheter. Radiology 229:99-108
23. Ajaj W, Pelster G, Treichel U, Vogt F (2003) Dark lumen magnetic resonance colonography: comparison with conventional colonoscopy for the detection of colorectal pathology. Gut 52:1738-1744
24. Tolan DJM, Greenhalgh R, Zealley IA, Halligan S, Taylor SA (2010) MR enterographic manifestations of small bowel Crohn disease. Radiographics 30:367-384
25. Ziech MLW, Bossuyt PMM, Laghi A, Lauenstein TC, Taylor SA, Stoker J (2012) Grading luminal Crohn's disease: which MRI features are considered as important? Eur J Radiol 81:e467-e472
26. Björkesten C-G, Nieminen U, Turunen U, Arkkila P, Sipponen T, Färkkilä M (2012) Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease. Scand J Gastroenterol 47:528-537
27. Rimola J, Ordás I, Rodríguez S, Ricart E, Panés J (2012) Imaging indexes of activity and severity for Crohn's disease: current status and future trends. Abdom Imaging 37:958-966
28. Sipponen T, Savilahti E, Kärkkäinen P et al (2008) Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease. Inflamm Bowel Dis 14:1392-1398
29. Eder P, Stawczyk-Eder K, Krela-KaÅmierczak I, Linke K (2008) Clinical utility of the assessment of fecal calprotectin in LeÅniowski- Crohn's disease. Pol Arch Med Wewn 118:622-626
30. Dolwani S, Metzner M, Wassell JJ, Yong A, Hawthorne AB (2004) Diagnostic accuracy of faecal calprotectin estimation in prediction of abnormal small bowel radiology. Aliment Pharmacol Ther 20:615-621
31. Lönnkvist MH, Theodorsson E, Holst M, Ljung T, Hellström PM (2011) Blood chemistry markers for evaluation of inflammatory activity in Crohn's disease during infliximab therapy. Scand J Gastroenterol 46:420-427
32. García-Sánchez V, Iglesias-Flores E, González R et al (2010) Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis? J Crohn's and Colitis 4:144-152
33. Kallel L, Ayadi I, Matri S et al (2010) Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study. Eur J Gastroenterol Hepatol 22:340-345
34. Louis E, Mary J-Y, Vernier-Massouille G et al (2012) Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 142:63-70
35. D'Incà R, Dal Pont E, Di Leo V et al (2008) Can calprotectin predict relapse risk in inflammatory bowel disease? Am J Gastroenterol 103:2007-2014
36. Lamb CA, Mohiuddin MK, Gicquel J et al (2009) Faecal calprotectin or lactoferrin can identify postoperative recurrence in Crohn's disease. Br J Surg 96:663-674
37. Sipponen T, Björkesten C-GAF, Färkkilä M, Nuutinen H, Savilahti E, Kolho K-L (2010) Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment. Scand J Gastroenterol 45:325-331
38. Pariente B, Cosnes J, Danese S et al (2011) Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis 17:1415-1422